MDXH Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 27.70
- PEG ratio
- —
- P/B
- 23.64
- P/S (TTM)
- 0.26
- EV/EBITDA
- 17.57
Profitability & growth
- ROE (TTM)
- -2440.0%
- Operating margin
- -26.7%
- Revenue growth YoY
- 12.7%
- Dividend yield
- —
- Beta
- -506982.72
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About MDxHealth SA ADR
Company profileMDxHealth SA is a leading biotechnology firm specializing in precision diagnostics for cancer management, with a primary focus on prostate and bladder cancers. Its flagship product, ConfirmMDx for Prostate Cancer, is recognized for its robust clinical efficacy and substantial market presence, reinforcing the company's commitment to advancing personalized medicine. As the demand for targeted cancer therapies rises, MDxHealth is strategically positioned to broaden its diagnostic portfolio, addressing significant unmet clinical needs in oncology while enhancing patient outcomes. The company's…
Classification
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- CAP BUSINESS CENTER, HERSTAL, BELGIUM
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
